AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37079158
Drug: Contribution of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contribution of discretionary salt to daily iodine intake
Trial: 34229267
Drug: Mixed oil
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed oil intravenous lipid emulsion (MO ILE)
Trial: 34229267
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil intravenous lipid emulsion (SO ILE)
Trial: 39040578
Drug: Brensocatib 10
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 10 mg
Trial: 39040578
Drug: Brensocatib 25
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 25 mg
Trial: 35411669
Drug: Brensocatib 40
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 40 mg
Trial: 35411669
Drug: Brensocatib 40
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 40 mg (with food)
Trial: 35411669
Drug: Brensocatib 40
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 40 mg (without food)
Trial: 33832949
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg once daily from day 1 to 14 every 3 weeks)
Trial: 32933755
Drug: hs‐cTnT peak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs‐cTnT peak value <3,500 ng/L
Trial: 34318438
Drug: Scheduled oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled oral regimen of ibuprofen plus acetaminophen (alternating every 3 hours or concurrent every 6 hours for 5 days)
Trial: 34318438
Drug: HTX-011 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (300 mg bupivacaine/9 mg meloxicam)
Trial: 34318438
Drug: HTX-011 with
RxNorm normalized name: Human papillomavirus virus-like particles conjugated with ir700 dye au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 with ibuprofen/acetaminophen
Trial: 33576284
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription (PAP)
Trial: 32828187
Drug: Community engagement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community engagement and community health worker-led mobile health-supported early detection, initial treatment, and hospital referral of women with hypertension.
Trial: 33433847
Drug: Danhong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong Injection (40 mL twice a day for a week)
Trial: 33433847
Drug: Statins intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins intensive group (atorvastatin 80 mg once, then 40 mg daily for 1 week)
Trial: 33433847
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (atorvastatin 10–20 mg daily for 1 week)
Trial: 33726903
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg or 30 mg once daily)
Trial: 33661141
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (0.05 μg·kg‐1·min‐1) for 30 min before spinal anesthesia
Trial: 33661141
Drug: Ephedrine bolus
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine bolus (0.15 mg/kg) before spinal anesthesia
Trial: 35398908
Drug: Music-only condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-only condition (sham treatment)
Trial: 32054731
Drug: Acalabrutinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 200 mg once daily
Trial: 35921114
Drug: 195 mg
RxNorm normalized name: aspirin 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 195 mg transdermal cannabidiol
Trial: 35921114
Drug: 390 mg
RxNorm normalized name: kaolin 390 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 390 mg transdermal cannabidiol
Trial: 34467639
Drug: Early-food supplementation
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-food supplementation (daily supplementation starting before 9 gestation weeks)
Trial: 34467639
Drug: Usual-food supplementation
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-food supplementation (daily supplementation starting at 20 gestation weeks)
Trial: 34467639
Drug: Prenatal supplementation
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplementation with 30-mg or 60-mg iron with 400-µg folic acid or multiple micronutrients (MM)
Trial: 33009977
Drug: Elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental diet (ELENTAL®) 160 g/day for 9 weeks during chemotherapy
Trial: 32631405
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A 25,000 IU daily, Vitamin D 600,000 IU once, Vitamin E 300 IU twice daily, Vitamin C four times per day, B vitamins daily (Soluvit)
Trial: 32631405
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplements or placebo)
Trial: 32100495
Drug: Suspension moxibustion
RxNorm normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension moxibustion combined with hormone therapy
Trial: 32100495
Drug: Hormone without
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone without moxibustion
Trial: 32100495
Drug: Hormone with
RxNorm normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone with moxibustion
Trial: 34687130
Drug: High M6-GGT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High M6-GGT levels (>25 U/L)
Trial: 34687130
Drug: High M6-GGT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High M6-GGT levels (>25 U/L) in non-cirrhotic patients
Trial: 35487727
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg alirocumab subcutaneously every 2 weeks for a total of 26 weeks
Trial: 35487727
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no alirocumab treatment)
Trial: 35081022
Drug: High-dose convalescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose convalescent plasma (CCP) transfusion (3 daily doses of 600 mL/d)
Trial: 35081022
Drug: High-dose convalescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose convalescent plasma (CCP) transfusion
Trial: 33237632
Drug: POG patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POG patients with WGTA-informed treatment change
Trial: 33764385
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (molecular inhibitor)
Trial: 33764385
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (cytotoxic therapy)
Trial: 33764385
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (hormone therapy)
Trial: 33764385
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (immune therapy)
Trial: 35727083
Drug: Esketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.5 mg/kg parenteral dose)
Trial: 34229074
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine intravenous infusion
Trial: 34229074
Drug: Simultaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous morphine + naloxone infusion
Trial: 32385061
Drug: PIFR-based optimised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIFR-based optimised inhalation therapy and training on inhaler usage at discharge
Trial: 33742764
Drug: RO6870868 (200–2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6870868 (200–2000 mg)
Trial: 35673907
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) + chemotherapy
Trial: 32942192
Drug: Contact intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact intervention for parents with supervised contact, involving increased preparation and support by caseworkers before and after contact visits
Trial: 35133982
Drug: Paclitaxel chemotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel chemotherapy
Trial: 33551142
Drug: Flapless implant
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flapless implant placement with immediate functional loading
Trial: 33551142
Drug: Flap implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap implant placement with immediate functional loading
Trial: 35446296
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioral therapy (TF-CBT) for 14 weeks with 2 weeks follow-up
Trial: 32253054
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 320/36/9.6 μg without spacer and no charcoal
Trial: 32253054
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 320/36/9.6 μg with spacer and no charcoal
Trial: 32253054
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 320/36/9.6 μg without spacer and with charcoal
Trial: 32253054
Drug: BGF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF MDI 320/36/9.6 μg with spacer and with charcoal
Trial: 34711975
Drug: Undisclosed self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undisclosed self-administration of suboptimal ART
Trial: 35448022
Drug: Traditional Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Cognitive Rehabilitation Group (TCRG) received standard cognitive treatment
Trial: 33128925
Drug: Cold-dry conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-dry conditions (CC, −20 °C, RH 40%)
Trial: 33593749
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg, orally, once daily for 24 weeks
Trial: 33593749
Drug: Pioglitazone 15-30
RxNorm normalized name: pioglitazone 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15-30 mg, orally, once daily for 24 weeks
Trial: 35667714
Drug: Investigational agents
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational agents (up to four agents)
Trial: 32114088
Drug: Vaccine blog
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine blog posts
Trial: 34018624
Drug: Randomization-based inference
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization-based inference for a marginal treatment effect in SWTs
Trial: 35872928
Drug: Acupotomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy and electroacupuncture therapy
Trial: 35872928
Drug: Hot compress,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot compress, oral medication, and local injection
Trial: 33645201
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone 1‐34 alone (Group A)
Trial: 33645201
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone 1‐34 plus Zoledronic Acid (ZA) (Group B)
Trial: 33482681
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of novel direct oral anticoagulants (DOACs)
Trial: 33541274
Drug: Colistin-based combination
RxNorm normalized name: colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin-based combination therapy
Trial: 35931948
Drug: Median nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median nerve block (5 ml of 0.5% lidocaine)
Trial: 35931948
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (subcutaneous local block)
Trial: 32866837
Drug: 10% imidacloprid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% imidacloprid + 2.5% moxidectin (topical once monthly for 9 months) and doxycycline (10 mg/kg twice daily for 28 days)
Trial: 32866837
Drug: Melarsomine dihydrochloride
RxNorm normalized name: melarsomine dihydrochloride
DrugBank: Melarsomine (DB11528)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melarsomine dihydrochloride (2.5 mg/kg, two injections 24 hours apart)
Trial: 35101883
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Trial: 35101883
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Trial: 35322711
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D supplementation (50,000 IU on the first day followed by 10,000 IU/day for 29 days)
Trial: 35322711
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 1000 IU vitamin D daily and a placebo soft gel
Trial: 33485328
Drug: Opioid-free perioperative
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free perioperative analgesic pathway
Trial: 33485328
Drug: Traditional opioid-including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Traditional opioid-including perioperative medications
Trial: 36915205
Drug: ENG‐IMPLANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENG‐IMPLANT
Trial: 36915205
Drug: DSG + ENG‐IMPLANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSG + ENG‐IMPLANT
Trial: 33476534
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate injection (5 mg/kg) at 1 hour before ventilator weaning
Trial: 33476534
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with caffeine
Trial: 32314327
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment of non-resectable, non-ablatable CLM
Trial: 32146720
Drug: SRP combined
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP combined with laser therapy
Trial: 32146720
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (SRP with and without laser therapy)
Trial: 35500223
Drug: Metformin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin for 6 months
Trial: 32584384
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (2 mg) monthly for 12 months
Trial: 32584384
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (2 mg) quarterly for 12 months
Trial: 32584384
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (2 mg) monthly or quarterly for 12 months
Trial: 33563325
Drug: Azithromycin plus
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin plus standard of care (500 mg qd for 5 days)
Trial: 33725432
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine (AZD1222), 5×10^10 viral particles, two doses 21 to 35 days apart
Trial: 33725432
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine (AZD1222)
Trial: 32493514
Drug: Tocilizumab (8mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8mg/kg body weight i.v. once, 12 mg/kg for patients <30kg BW, max 800 mg)
Trial: 35194818
Drug: 6-week lifestyle
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week lifestyle medicine program consisting of five lifestyle factors
Trial: 32142556
Drug: Rhythmic sensory
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rhythmic sensory stimulation (RSS) treatment with different parameters
Trial: 32142556
Drug: Rhythmic sensory
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rhythmic sensory stimulation (RSS) treatment with different specifications
Trial: 35331538
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg/day for 24 weeks)
Trial: 32121218
Drug: Low-dose DYM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DYM (100 mg)
Trial: 32121218
Drug: High-dose DYM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DYM (150 mg)
Trial: 32121218
Drug: Low-dose DYM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DYM with TCR (100 mg + 50 mg)
Trial: 32121218
Drug: High-dose DYM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DYM with TCR (150 mg + 25 mg)
Trial: 35848979
Drug: Acupuncture therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapies combined with swallowing training
Trial: 33580200
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving ≥2 lines of treatment
Trial: 34116700
Drug: Topical rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rVA576 eye drops, administered twice a day for 8 weeks
Trial: 34116700
Drug: Topical rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rVA576 eye drops
Trial: 33075444
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - received a brochure with supplementary advice, tips, and monthly counselling on food texture introduction.
Trial: 32369631
Drug: Prednisone Therapy
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone Therapy
Trial: 32886447
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) monotherapy (150 mg twice daily)
Trial: 32886447
Drug: Combined Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combined Pregabalin (PGB) (150 mg twice daily) and Milnacipran (MLN) (50 mg twice daily)
Trial: 32195927
Drug: Daily educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily educational text messages on diabetes and reminders for 6 months
Trial: 32182123
Drug: Canagliflozin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (600 mg)
Trial: 35197356
Drug: Volatile sedatives
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile sedatives
Trial: 35197356
Drug: Intravenous sedatives
RxNorm normalized name: Sed-Max
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedatives